Vol. 00, No. 00, 2019
de Salles et al.
3
120 ºC under vacuum for 10 h. The specific surface areas
were determined by the Brunauer-Emmett-Teller (BET)
multipoint technique and the pore size distribution curves
were obtained by using the Barrett-Joyner-Halenda (BJH)
and density functional theory (DFT) methods.
4.28 (s, 2H), 3.61 (s, 3H); 13C NMR (101 MHz, CDCl3)
d 157.1, 144.9, 141.6, 137.4, 132.3, 129.5, 128.7, 128.1,
126.5, 123.8, 123.6, 120.8, 119.7, 117.7, 111.9, 110.9,
55.2, 30.3.
3‑Benzyl‑2‑(3‑methoxyphenyl)imidazo[1,2‑a]pyridine (4c)49
1
General procedure for the synthesis of Cu/SiO2 material 2
Yield 81% (254.7 mg); H NMR (400 MHz, CDCl3)
d 7.71-7.65 (m, 2H), 7.38-7.19 (m, 6H), 7.18-7.10 (m, 3H),
6.93-6.87 (m, 1H), 6.68 (t, J 6.8 Hz, 1H), 4.48 (s, 2H), 3.78
(s, 3H); 13C NMR (100 MHz, CDCl3) d 159.9, 144.9, 143.9,
136.0, 129.5, 129.0, 127.7, 127.0, 124.2, 123.4, 120.6,
117.9, 117.6, 114.1, 113.3, 112.3, 55.3, 29.9.
In a vial flask adapted with a magnetic bar were added
5 mL of ethanol, 2 mL of deionized water and 1 drop
(circa 50 µL) of hydrofluoric acid. Then, it was added
CuCl2 (1.2 mmol, 0.150 g) and the solution stirred until
complete homogenization. The mixture was poured onto
tetraethyl orthosilicate (TEOS, 22.4 mmol, 5.0 mL), stirred
until complete homogenization and after the formation of
a translucid glassy material (gelation), the vial was closed
and kept under heating (40 ºC) for 7 days. After this time,
the vial cap was removed and kept under mild heating
(30 ºC) for more 7 days for slow solvent evaporation.
The solid was then removed from the vial, powdered and
treated at high temperature (300 ºC) for 4 h while during
this process the material color change from green to dark
brown. After cooling, the green powder was washed with
distilled water (3 × 20 mL) and ethanol (20 mL) and then
dried at 100 ºC for 24 h.
3‑Benzyl‑2‑(4‑methoxyphenyl)imidazo[1,2‑a]pyridine (4d)38
1
Yield 72% (226.4 mg); H NMR (400 MHz, CDCl3)
d 7.72 (d, J 8.7 Hz, 2H), 7.67-7.60 (m, 2H), 7.35-7.20 (m,
3H), 7.18-7.07 (m, 2H), 6.96 (d, J 8.7 Hz, 2H), 6.66 (td,
J 6.8, 2.2 Hz, 1H), 4.45 (s, 2H), 3.82 (s, 3H); 13C NMR
(100 MHz, CDCl3) d 159.3, 144.8, 144.0, 136.9, 129.3,
129.0, 127.7, 127.1, 126.8, 123.9, 123.2, 117.3, 117.0,
114.1, 112.0, 55.3, 29.9.
3‑Benzyl‑2‑(2‑fluorophenyl)imidazo[1,2‑a]pyridine (4e)48
Yield 78% (236.0 mg); 1H NMR (400 MHz, CDCl3) d
7.73 (td, J 7.5, 1.8 Hz, 1H), 7.69-7.62 (m, 2H), 7.34 (m,
1H), 7.28-7.05 (m, 8H), 6.65 (dt, J 6.6, 3.3 Hz, 1H), 4.34
(s, 2H); 13C NMR (100 MHz, CDCl3) d 161.3, 158.8, 145.2,
139.1, 136.8, 132.2, 129.9, 129.8, 128.9, 128.0, 126.8,
124.5, 124.4, 124.2, 123.8, 122.7, 122.5, 119.8, 117.8,
116.1, 115.9, 112.2, 30.1.
General procedure for the A3‑coupling to substituted
imidazo[1,2‑a]pyridines
In a Schlenk tube under inert atmosphere were added
2-aminopyridine (1.1 mmol, 0.112 g), aldehyde (1.0 mmol),
Cu/SiO2 (10 mol%), terminal alkyne (1.5 mmol) and
toluene (0.5 mL). The mixture was heated to 120 °C and
stirred for 48 h. The mixture was then filtered and the
solvent removed under vacuum and the crude product was
purified by column chromatography with hexanes, ethyl
acetate and triethylamine (84:10:4) as eluent.
3‑Benzyl‑2‑(3‑fluorophenyl)imidazo[1,2‑a]pyridine (4f)
1
Yield 71% (214.5 mg); H NMR (400 MHz, CDCl3)
d 7.71-7.64 (m, 2H), 7.54 (d, J 7.5 Hz, 2H), 7.36 (dd,
J 14.2, 7.5 Hz, 1H), 7.32-7.21 (m, 3H), 7.21-7.14 (m, 1H),
7.12 (d, J 7.4 Hz, 2H), 7.06-6.99 (m, 1H), 6.73-6.66 (m,
1H), 4.48 (s, 2H); 13C NMR (100 MHz, CDCl3) d 164.4,
161.9, 145.0, 143.0, 137.0, 136.9, 136.6, 130.2, 130.1,
129.2, 127.7, 126.1, 124.5, 123.8, 123.8, 123.5, 118.2,
117.8, 115.3, 115.1, 114.7, 114.5, 112.5, 29.9; HRMS
(ESI) m/z, calcd. for C20H15N2F [M + H]+: 303.1298,
found: 303.1293.
3‑Benzyl‑2‑phenylimidazo[1,2‑a]pyridine (4a)38
1
Yield 68% (193.3 mg); H NMR (400 MHz, CDCl3)
d 7.79 (d, J 7.4 Hz, 2H), 7.67 (d, J 8.7 Hz, 2H), 7.42 (t,
J 7.5 Hz, 2H), 7.36-7.20 (m, 4H), 7.18-7.10 (m, 3H), 6.67
(t, J 6.9 Hz, 1H), 4.48 (s, 2H); 13C NMR (100 MHz, CDCl3)
d 144.8, 144.1, 136.7, 134.5, 128.9, 128.5, 128.1, 127.6,
126.8, 124.0, 123.3, 117.6, 117.5, 112.1, 29.8.
3‑Benzyl‑2‑(4‑fluorophenyl)imidazo[1,2‑a]pyridine (4g)38
1
Yield 82% (248.0 mg); H NMR (400 MHz, CDCl3)
d 7.77-7.71 (m, 2H), 7.71-7.64 (m, 2H), 7.34-7.24 (m,
3H), 7.21-7.15 (m, 1H), 7.14-7.08 (m, 4H), 6.71 (td, J 6.8,
1.0 Hz, 1H), 4.46 (s, 2H); 13C NMR (100 MHz, CDCl3)
d 163.9, 161.5, 145.0, 143.4, 136.8, 130.8, 130.0, 129.9,
129.2, 127.8, 127.1, 124.3, 123.5, 117.7, 115.8, 115.6,
112.4, 29.9.
3‑Benzyl‑2‑(2‑methoxyphenyl)imidazo[1,2‑a]pyridine (4b)35
1
Yield 64% (201.2 mg); H NMR (400 MHz, CDCl3)
d 7.67-7.61 (m, 3H), 7.35 (td, J 8.3, 1.8 Hz, 1H), 7.26-
7.17 (m, 3H), 7.15-7.10 (m, 3H), 7.05 (td, J 7.5, 0.8 Hz,
1H), 6.95 (d, J 8.2 Hz, 1H), 6.65 (td, J 6.8, 1.0 Hz, 1H),